Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q1 2022 · 10-Q
Revenue—
Net Income-$14.46M-$14.46MN/M vs Q1 2021 EPS Diluted-$0.08-$0.08N/M vs Q1 2021 Operating Income-$13,149,681N/M Operating Cash Flow-$10,990,258N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 14, 2022 · 45 d after period end